4D Biomaterials secures £1.6m funding
4D Biomaterials, which has developed a new biomaterial used for 3D printing medical implants, has completed a £1.6m funding round.
The investment was led by DSW Ventures and backed by the MEIF Proof of Concept & Early Stage Fund, which is managed by Mercia and part of the Midlands Engine Investment Fund, Mercia’s own funds, and existing investor SFC Capital.
The funding will be used to develop a range of products through partnerships with medical device companies and expand its team with the creation of five new jobs at its premises in MediCity.
Dr James Lapworth, Warwick Innovations, who has worked closely with the founding team since 2017 to support their ICURe customer discovery process, said: “This oversubscribed investment round into 4D Biomaterials recognises the progress that the team has made since spinning out, as well as the market opportunities which the company’s unique range of biodegradable 3D printing materials could address.”
NanoSyrinx raises £6.2m to develop its synthetic biology platform for targeted intracellular engineering
Coventry, United Kingdom, 19th July 2021 – NanoSyrinx, a biotech company developing a new cell engineering tool for novel targeted therapeutic modalities, has raised a further £6.2m of seed financing, co-led by incoming Octopus Ventures and existing investor M Ventures (Amsterdam, The Netherlands), the corporate venture capital arm of Merck KGaA. Previous investors BioCity and the UK Innovation & Science Seed Fund (UKI2S) joined the funding round along with experienced deeptech investor IQ Capital and Jonathan Milner. The round was significantly oversubscribed with high demand both from existing and from new investors.
Dr James Lapworth, Warwick Innovations, who has worked closely with the founding team since 2016 to develop the commercialisation strategy for the technology, said: “This latest investment into NanoSyrinx is a huge vote of confidence in the technology and in the team. It recognises not only the potential impact that nanosyringes could have as advanced medicines but also the entrepreneurial talent emerging from our researcher community.”
For commercial enquiries contact Dr James Lapworth, Warwick Innovations, email: email@example.com
Diagnostic tool for Coronavirus being developed by University of Warwick makes significant step forward
New study published on rapid test for Coronavirus being developed by University of Warwick demonstrates detection using a model virus rather than just proteins. The diagnostic tool will function without any need for training or complex infrastructure, looking like a ‘pregnancy test’. The team are seeking philanthropic or investment partners to develop and take forward this new technology
The work being done at University of Warwick, in collaboration with Iceni Diagnostics, around developing a new approach to rapid coronavirus diagnostics has been featured on the BBC. On Thursday 25 June, BBC Midlands interviewed Professor Gibson and members of his team - a feature on this can be read on the BBC News web pages. You can also see the news report video here.
Verdel is a UK-based company pushing the boundaries of complex sample analysis using innovative Two-Dimensional Mass Spectrometry (2DMS) technology
Our investor days will showcase 15 new University Spinout companies who have participated in the award winning Innovate UK funded ICURe (Innovation to Commercialisation of University Research) programme and are now seeking early-stage funding and entrepreneurial managers.
Humane Technologies Limited (HTL) has announced that it has successfully developed a prototype for the next generation of its microbial growth measurement device, the MicrobeMeter.
Verdel Instruments Ltd - a spin-out company of the University of Warwick UK – has developed new disruptive two-dimensional mass spectrometry (2DMS) technology and raised seed investment of over £230,000 from Longwall Ventures and Innovate UK.
Warwick University spinout, Spectra Analytics, has been awarded £1m by Innovate UK to improve Primary Care using AI
Medherant Limited, the clinical-stage developer of innovative transdermal delivery products for pain and CNS diseases using its unique TEPI Patch® technology, has today announced a new £2 million investment from Mercia Technologies PLC.